Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 421

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Wang, Jie, Zhou, Caicun, Yao, Wenxiu, Wang, Qiming, Min, Xuhong, Chen, Gongyan, Xu, Xingxiang, Li, Xingya, Xu, Fei, Fang, Yong, Yang, Runxiang, Yu, Guohua, Gong, Youling, Zhao, Jun, Fan, Yun, Liu, Quan, Cao, Lejie, Yao, Yu, Liu, Yunpeng, Li, Xiaoling, Wu, Jingxun, He, Zhiyong, Lu, Kaihua, Jiang, Liyan, Hu, Chengping, Zhao, Wenhua, Zhang, Ben, Shi, Wei, Zhang, Xiaojing, Cheng, Ying, Cheng, Ying, Wang, Jie, Zhou, Caicun, Yao, Wenxiu, Wang, Qiming, Min, Xuhong, Chen, Gongyan, Xu, Xingxiang, Li, Xingya, Xu, Fei, Fang, Yong, Yang, Runxiang, Yu, Guohua, Gong, Youling, Zhao, Jun, Fan, Yun, Liu, Quan, Cao, Lejie, Yao, Yu, Liu, Yunpeng, Li, Xiaoling, Wu, Jingxun, He, Zhiyong, Lu, Kaihua, Jiang, Liyan, Hu, Chengping, Zhao, Wenhua, Yu, Huiqing, Zhao, Jian, Wu, Gang, Huang, Dingzhi, Chen, Chengshui, Ding, Cuimin, Zhang, Baihong, Wang, Xiuwen, Luo, Hui, Li, Baolan, Zhang, Shucai, Lu, Hong, Shi, Meiqi, Chen, Xi, Guo, Yubiao, Liu, Hailong, Liu, Jiwei, Gao, Hongjun, Hu, Sheng, Hong, Qunying, Li, Qi, Zhang, Ben, Shi, Wei, Zhang, Xiaojing·2022·The Lancet Oncology

Abstract

BACKGROUND Extensive-stage small-cell lung cancer (ES-SCLC) is associated with poor prognosis and treatment options are scarce. Immunotherapy has shown robust clinical activity in ES-SCLC in previous phase 3 trials. We aimed to assess the efficacy and safety of adebrelimab (SHR-1316), a novel anti-PD-L1 antibody, with standard chemotherapy as a first-line treatment for ES-SCLC. METHODS The CAPSTONE-1 study was a randomised, double-blind, placebo-controlled, phase 3 trial, done in 47 tertiary hospitals in China. Key inclusion criteria were patients aged 18-75 years, with previously untreated histologically or cytologically confirmed ES-SCLC and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Eligible patients were randomly assigned (1:1) to receive four to six cycles of carboplatin (area under the curve of 5 mg/mL per min, day 1 of each cycle) and etoposide (100 mg/m2 of body-surface area, on days 1-3 of each cycle) with either adebrelimab (20 mg/kg, day 1 of each cycle) or matching placebo, followed by maintenance therapy with adebrelimab or placebo. All treatments were given intravenously in 21-day cycles. Randomisation was done using a centralised interactive web response system with a block size of four, stratified by liver metastases, brain metastases, and lactate dehydrogenase concentration. The primary endpoint was overall survival in patients who received at least one dose of study medication. Safety was analysed in the as-treated population. This study is complete and registered with ClinicalTrials.gov, NCT03711305. FINDINGS Between Dec 26, 2018, and Sept 4, 2020, 462 eligible patients were enrolled and randomly assigned: 230 (50%) patients received adebrelimab plus chemotherapy (adebrelimab group) and 232 (50%) patients received placebo plus chemotherapy (placebo group). At data cutoff (Oct 8, 2021), median follow-up was 13·5 months (IQR 8·9-20·1). Median overall survival was significantly improved in the adebrelimab group (median 15·3 months [95% CI 13·2-17·5]) compared with the placebo group (12·8 months [11·3-13·7]; hazard ratio 0·72 [95% CI 0·58-0·90]; one-sided p=0·0017). The most common treatment-related grade 3 or 4 adverse events were decreased neutrophil count (174 [76%] patients in the adebrelimab group and 175 [75%] patients in the placebo group), decreased white blood cell count (106 [46%] and 88 [38%]), decreased platelet count (88 [38%] and 78 [34%]), and anaemia (64 [28%] and 66 [28%]). Treatment-related serious adverse events occurred in 89 (39%) patients in the adebrelimab group and 66 (28%) patients in the placebo group. Four treatment-related deaths were reported: two each in the adebrelimab group (respiratory failure and interstitial lung disease and pneumonia) and placebo group (multiple organ dysfunction and unknown cause of death). INTERPRETATION Adding adebrelimab to chemotherapy significantly improved overall survival with an acceptable safety profile in patients with ES-SCLC, supporting this combination as a new first-line treatment option for this population. FUNDING Jiangsu Hengrui Pharmaceuticals.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(22)00224-8

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 421

Metadata

Authors
Wang, J., Zhou, C., Yao, W., Wang, Q., Min, X., Chen, G., Xu, X., Li, X., Xu, F., Fang, Y., Yang, R., Yu, G., Gong, Y., Zhao, J., Fan, Y., Liu, Q., Cao, L., Yao, Y., Liu, Y., Li, X., Wu, J., He, Z., Lu, K., Jiang, L., Hu, C., Zhao, W., Zhang, B., Shi, W., Zhang, X., Cheng, Y., Cheng, Y., Wang, J., Zhou, C., Yao, W., Wang, Q., Min, X., Chen, G., Xu, X., Li, X., Xu, F., Fang, Y., Yang, R., Yu, G., Gong, Y., Zhao, J., Fan, Y., Liu, Q., Cao, L., Yao, Y., Liu, Y., Li, X., Wu, J., He, Z., Lu, K., Jiang, L., Hu, C., Zhao, W., Yu, H., Zhao, J., Wu, G., Huang, D., Chen, C., Ding, C., Zhang, B., Wang, X., Luo, H., Li, B., Zhang, S., Lu, H., Shi, M., Chen, X., Guo, Y., Liu, H., Liu, J., Gao, H., Hu, S., Hong, Q., Li, Q., Zhang, B., Shi, W., & Zhang, X.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2022-06
Volume
23
Issue
6
Pages
739-747
ISSN
1470-2045 (ISSN-L)
OpenAlex
W4280546819
Cited by
421
References
19
FWCI
30.27
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(22)00224-8
The paper
Wang, J., Zhou, C., Yao, W., Wang, Q., Min, X., Chen, G., Xu, X., Li, X., Xu, F., Fang, Y., Yang, R., Yu, G., Gong, Y., Zhao, J., Fan, Y., Liu, Q., Cao, L., Yao, Y., Liu, Y., . . . Zhang, X. (2022). Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(22)00224-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.